Back
MOTE ATTENDS ASGCT 2025
May 14, 2025
2 min read
Mote therapeutics presented preclinical data for its mobilize TM LNPs in humanized mice and NHP animal models and updates on early T cell program at ASGCT2025.
MOTE Therapeutics is an innovative preclinical-stage startup building the RNA medicines of tomorrow. We are backed by Fapon Biotech, an international leader in in vitro diagnostics, biologics, and precision medicine. We started our operations in Massachusetts in July 2024 and currently have a team of 25 scientists. Led by a pioneer in the field of LNP-based targeted delivery technologies for RNA therapeutics and supported by Fapon's Greater Boston R&D Center of excellence, we are assembling a team of talented scientists, leaders, and operations specialists to solve some of the major barriers to success that RNA therapeutics face.
Our mobilize TM (MOTE BIfunctional LocalIZEr) technology provides a simple and elegant way to generate a targeted LNP platform that is highly modular and solves the scale-up and manufacturing challenges that have proven to be the most significant bottleneck for translation. We are a cargo-agnostic delivery platform company focused on pioneering a pipeline of novel RNA-based, tissue-targeted drug products to benefit patients suffering from hematological malignancies, solid tumors, CNS diseases, and genetic diseases.
